Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 31, 2020 07:00 ET | Source: Nabriva Therapeutics US, Inc

Nabriva Therapeutics to Participate in Upcoming Virtual Investor Conferences

DUBLIN, Ireland, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective...
August 06, 2020 16:01 ET | Source: Nabriva Therapeutics US, Inc

Nabriva Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Updates

-SIVEXTRO® adds revenue generating product creating additional scale and synergies- -Relaunch of XENLETA® and SIVEXTRO planned with targeted in-person promotion- -Conference call today at 4:30...
August 03, 2020 07:00 ET | Source: Nabriva Therapeutics US, Inc

Nabriva Therapeutics to Report Second Quarter 2020 Financial Results on August 6, 2020

DUBLIN, Ireland, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective...
July 30, 2020 16:01 ET | Source: Nabriva Therapeutics US, Inc

Nabriva Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

DUBLIN, Ireland, July 30, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective...
July 28, 2020 10:02 ET | Source: Nabriva Therapeutics US, Inc

NABRIVA Receives European Approval for XENLETA® (lefamulin) for Treatment of Community-Acquired Pneumonia (CAP)

-XENLETA represents the first new antibiotic class approved for patients with CAP in Europe in nearly 20 years -XENLETA approval provides urgently needed short-course, empiric monotherapy treatment...
July 23, 2020 07:00 ET | Source: Nabriva Therapeutics US, Inc

Lefamulin Demonstrates Anti-Inflammatory Activity in Pre-Clinical Study

-In pre-clinical model, lefamulin shows anti-inflammatory activity comparable to dexamethasone -Nabriva awarded grant funding from the Austrian Research Promotion Agency to further characterize the...
July 16, 2020 16:04 ET | Source: Nabriva Therapeutics US, Inc

XENLETA® (lefamulin) Receives Health Canada Approval for Treatment of Community Acquired Pneumonia

DUBLIN, Ireland, July 16, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective...
July 15, 2020 16:01 ET | Source: Nabriva Therapeutics US, Inc

Nabriva Therapeutics Enters into Exclusive Agreement to Promote and Distribute SIVEXTRO® (tedizolid phosphate) in the U.S.

Accretive transaction creates synergies and scale that strengthen Nabriva’s community-focused commercialization organization to optimize product uptake Nabriva partners with Amplity Health to provide...
June 19, 2020 20:52 ET | Source: Nabriva Therapeutics US, Inc

Nabriva Therapeutics Receives Complete Response Letter from FDA on NDA for CONTEPO™ (fosfomycin) for injection

DUBLIN, Ireland, June 19, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective...
May 29, 2020 19:31 ET | Source: Nabriva Therapeutics US, Inc

Nabriva Therapeutics Announces $38 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

DUBLIN, Ireland and KING OF PRUSSIA, Pa., May 29, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of...